Table 1.

Selected ongoing clinical trials in metastatic pancreatic adenocarcinoma

Clinical trials identifierStudy titleStagePhase
Cytotoxic chemotherapy
NCT02352337Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus FIRGEM in First-lineIVII
NCT02620800Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer (FABLOx)IVII
NCT02551991A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic AdenocarcinomaIVII
NCT02184195A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based ChemotherapyIVIII
CXCL12/CXCR4 axis
NCT02826486A Phase II, Multicenter, Open-label Single Arm Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT StudyIVII
CSF1/CSF1R axis
NCT02777710A Dose Escalation Phase I Study With an Extension Part Evaluating the Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With a Small Molecule CSF-1R Tyrosine Kinase Inhibitor (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersIII/IVI
CCL2/CCR2 axis
NCT02732938Ph1b/2 Study of Pf-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i)IVIb/II
NCT02715804A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal AdenocarcinomaIVIII
  • Abbreviations: BRCA, breast cancer; CCR2i, CC-chemokine receptor 2 inhibitor; FOLFIRINOX, folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin; nab-paclitaxel, albumin-bound paclitaxel.